Clinical Nuclear Medicine

Skip Navigation LinksHome > January 2013 - Volume 38 - Issue 1 > Comparative Effectiveness of 18F-FDG PET/CT Versus Whole-Bod...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318266ce84
Original Articles

Comparative Effectiveness of 18F-FDG PET/CT Versus Whole-Body MRI for Detection of Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Derlin, Thorsten MD*; Tornquist, Katharina MD*; Münster, Silvia MD; Apostolova, Ivayla MD; Hagel, Christian MD§; Friedrich, Reinhard E. MD; Wedegärtner, Ulrike MD*; Mautner, Victor F. MD

Collapse Box

Abstract

Purpose: The aim of this study was to compare the diagnostic performance of 18F-fluorodeoxyglucose (FDG) PET/CT and whole-body MRI for the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1, and to evaluate a panel of imaging-based criteria serving that purpose.

Patients and Methods: Thirty-one patients were examined by whole-body MRI and 18F-FDG PET/CT. A panel of imaging-based criteria including tumor region, size, shape, margin definition, contrast enhancement, heterogeneity before and after contrast, intratumoral lobulation, target sign, and mean and maximum standardized uptake values (SUVs) were evaluated. A SUVmax cut-off value of 3.5 was used for lesion analysis. Histopathologic evaluation and/or clinical follow-up served as the reference standard.

Results: 18F-FDG PET/CT had a sensitivity of 100%, whereas MRI had a sensitivity of 66.7%. On PET/CT, tumor size (P < 0.005), SUVmax (P < 0.0001), SUVmean (P < 0.0001), and tracer uptake heterogeneity (P = 0.002) were significantly associated with MPNSTs. On MRI, intratumoral lobulation (P < 0.02), ill-defined margins (P = 0.007), and irregular enhancement on T1-weighted imaging (P < 0.001) were significantly associated with MPNSTs.

Conclusions: Both PET/CT and whole-body MRI may distinguish benign and malignant PNSTs, but PET/CT has higher sensitivity for that purpose. Imaging-based criteria for identification of MPNSTs on both modalities were identified. False-positive results, requiring biopsy or clinical follow-up, may be reduced by using a combination of MRI and PET derived markers, but only at the price of reduced sensitivity.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.